Optimer Pharma (OPTR) Reports Superior Performance from DIFICID Phase 3 vs. Oral Vancomycin
Go back to Optimer Pharma (OPTR) Reports Superior Performance from DIFICID Phase 3 vs. Oral VancomycinOptimer Pharmaceuticals, Inc. (NASDAQ: OPTR) | Delayed: 12.78 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $12.78 | 52 Week High | $16.80 | |||
Open | $12.78 | 52 Week Low | $8.64 | |||
Day High | $12.78 | P/E | N/A | |||
Day Low | $12.78 | EPS | $-1.75 | |||
Volume | 1,179,540 |